-
AstraZeneca to strengthen cooperation with China
31 Jan 2026 01:42 GMT
… and Beijing. Medicines produced in China are supplied domestically and exported to more than 70 markets … Chinese biotechnology companies remains a cornerstone of AstraZeneca's China strategy. The company said the investment …
-
AstraZeneca to invest $15B in manufacturing, R&D in China through 2030
31 Jan 2026 01:17 GMT
… country — the company’s second-largest market.
China is currently home … diseases. The site will produce drug substances for AstraZeneca … $2.5 billion investment in Beijing over the next five … in biotechnology and manufacturing.
As part of the investment, …
-
Dhaka-Beijing co-op must continue: Says Yunus
31 Jan 2026 00:41 GMT
… included senior Chinese academics, investors, and industry leaders from … director of Walvax Biotech (Singapore), also expressed … standing relationship with China, which began … business models in the pharmaceutical sector.
“Medicines cost pennies to produce …
-
How China rewrote the rules of drug innovation
30 Jan 2026 23:45 GMT
… Beijing five to seven years later. This “China-Last” penalty rendered Chinese … investment.
State-backed funds co-invested alongside private venture capital, with biotech … healthcare, industry, and science ministries.
China’s domestic market is hypercompetitive …
-
AstraZeneca plans $15 B investment in China to expand medicines manufacturing and R&D
30 Jan 2026 23:25 GMT
… bring Chinese innovation to the world through our partnerships with leading biotechs … Beijing, which provide high-quality medicines to patients in China and 70 markets … , these investments will grow the Company’s highly skilled workforce in China beyond …
-
Xi Jinping says 'epoch-making technological transformation' of AI can change the human race - but unsurprisingly wants Chinese firms to lead the way
30 Jan 2026 22:37 GMT
… comparable to quantum computing and biotechnology, and likened it to … Over a year ago, Chinese AI company DeepSeek released a large … , features and guidance your business needs to succeed!
By … existing infrastructure.
This suggests Beijing’s approach may focus …
-
STAT+: AstraZeneca looks to China for obesity drug candidates
30 Jan 2026 20:03 GMT
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Oh, hi. Today, we discuss delays in the launch of TrumpRx. Also, Sanofi is deprioritizing its mRNA flu vaccine.
The need-to-know …
-
MYC Targeting Therapies Market Research Report 2026-2030, Profiles of Genetic Leap, Curigin, IDP Pharma, Incurix, Omega, Panavance, Peptomyc, Suzhou Kintor, Wayfinder Biosciences, WebenPharma - ResearchAndMarkets.com
30 Jan 2026 18:04 GMT
… Clinical Trials Insight by Company, Country, Indication … for partnership or investment.
This report provides … concept datasets.
The investors, partners, and competitors … SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2026 …
-
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
30 Jan 2026 16:45 GMT
… invest further into China’s biotechnology industry into action, striking … vast ecosystem of biotechs quickly developing therapies … or on the market. More than 60 … company had formed collaborations with Regeneron Pharmaceuticals and China-based biotech …
-
Pentagon Raises Alarm Over China’s Military-Civil Fusion Strategy
30 Jan 2026 17:06 GMT
… warfare, aligning all of Chinese society, including industry, infrastructure, technology, and … war closely with Beijing’s ambitions toward Taiwan, suggesting the country … highlights China’s growing emphasis on AI, semiconductors, and biotech, technologies …